Company Overview of PTC Therapeutics, Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company’s lead product is Translarna (ataluren), which is in Phase III clinical trials for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and for the treatment of cystic fibrosis caused by nonsense mutations. It also intends to develop Translarna for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, as well as develops spinal muscular atrophy, which is in Phase II clinical program. The company’s preclinical developme...
100 Corporate Court
South Plainfield, NJ 07080
Founded in 1998
Key Executives for PTC Therapeutics, Inc.
Co-Founder, Chief Executive Officer and Executive Director
Total Annual Compensation: $460.8K
Chief Commercial Officer
Total Annual Compensation: $368.2K
Compensation as of Fiscal Year 2013.
PTC Therapeutics, Inc. Key Developments
PTC Therapeutics Appoints Eric Pauwels as Senior Vice President and General Manager Commercial Operations, Americas
Apr 8 15
PTC Therapeutics, Inc. announced the appointment of Eric Pauwels as Senior Vice President and General Manager Commercial Operations, Americas. Eric will be responsible for the commercial strategy, organizational build out and launch of Translarna in the US, Canada and Latin America. Eric brings 33 years of global healthcare experience from several top-tier US and global pharmaceutical companies. Most recently, Eric was the Chief Commercial Officer at NPS Pharmaceuticals and President of NPS Pharmaceuticals International. At NPS, Eric built global commercial operations for the launch of Gattex/Revestive and prepared the pre-launch strategy for Natpara, both orphan biological therapies approved by the FDA for patients suffering from rare gastrointestinal and endocrine diseases.
PTC Therapeutics Announces Translarna™ Access Program in Duchenne Muscular Dystrophy for Siblings of Patients Participating in PTC Clinical Trials
Mar 3 15
PTC Therapeutics, Inc. announced that it will make Translarna available for siblings of patients in certain open label PTC clinical trials for nonsense mutation Duchenne muscular dystrophy (nmDMD). Translarna will be made available to these siblings in advance of commercial availability in their regions, after a treating physician and the patient or guardian make a clinical decision to use Translarna, and consistent with any other applicable regulatory requirements. Translarna, discovered and developed by PTC Therapeutics, Inc., is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein. The resulting disorder is determined by which protein cannot be expressed in its entirety and is no longer functional, such as dystrophin in Duchenne muscular dystrophy. Translarna is licensed in the European Economic Area for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged five years and older. Translarna is an investigational new drug in the United States. The development of Translarna has been supported by grants from Cystic Fibrosis Foundation Therapeutics Inc. (the nonprofit affiliate of the Cystic Fibrosis Foundation); Muscular Dystrophy Association; FDA'sOffice of Orphan Products Development; National Center for Research Resources; National Heart, Lung, and Blood Institute; and Parent Project Muscular Dystrophy.
PTC Therapeutics, Inc. Presents at Barclays Global Healthcare Conference, Mar-10-2015 08:00 AM
Feb 27 15
PTC Therapeutics, Inc. Presents at Barclays Global Healthcare Conference, Mar-10-2015 08:00 AM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Tuyen Ong, Senior Vice President and Head of Clinical Development & Translational Research.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|